- $354.66m
- $771.38m
- $512.12m
- 62
- 57
- 95
- 82
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 28.54 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.71 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -16.66% | ||
| Return on Equity | -39.19% | ||
| Operating Margin | -21.55% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 319.18 | 340.14 | 321.16 | 430.9 | 512.12 | 500.9 | 528.03 | 11.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -81.43 | +535.56 | +24.52 | +403.48 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bioventus Inc. is a medical device company. The Company is focused on developing and commercializing clinically differentiated and minimally invasive treatments that engage and enhance the body’s natural healing process. Its portfolio of products is grouped into three areas. Its Pain Treatments include non-surgical pain injection therapies as well as peripheral nerve stimulation (PNS) products to help the patient get back to their normal activities. Its Surgical Solutions include bone graft substitutes (BGS) that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries, as well as a portfolio of ultrasonic products used for precise bone cutting and sculpting, soft tissue management and tissue debridement in various surgeries. Its Restorative Therapies comprise a bone stimulation system, as well as devices designed to help patients regain leg or hand function due to stroke, multiple sclerosis or other central nervous system disorders.
Directors
- William Hawkins NEC (67)
- Kenneth Reali CEO (55)
- Gregory Anglum CFO (50)
- Alessandra Pavesio SVP (54)
- Katrina Church SVP (59)
- Anthony D'adamio SVP (60)
- Sharon Klugewicz SVP (53)
- John Nosenzo OTH (63)
- Mary Ladone DRC (55)
- Patrick Beyer IND
- Philip Cowdy IND (53)
- Michelle Mcmurry - Heath IND
- Guido Neels IND (72)
- Guy Nohra IND (60)
- Susan Stalnecker IND (68)
- Martin Sutter IND (66)
- Stavros Vizirgiankis IND
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- December 22nd, 2015
- Public Since
- February 11th, 2021
- No. of Employees
- 970
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 79,165,540
- Address
- 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM, 27703
- Web
- https://www.bioventus.com/
- Phone
- +1 9194746700
- Auditors
- Grant Thornton LLP
Upcoming Events for BVS
Bioventus Inc Annual Shareholders Meeting
Bioventus Inc Annual Shareholders Meeting
Q2 2024 Bioventus Inc Earnings Release
Similar to BVS
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the Bioventus share price?
As of Today at 19:04 UTC, shares in Bioventus are trading at $4.48. This share price information is delayed by 15 minutes.
How has the Bioventus share price performed this year?
Shares in Bioventus last closed at $4.48 and the price had moved by +354.5% over the past 365 days. In terms of relative price strength the Bioventus share price has outperformed the S&P500 Index by +278.22% over the past year.
What are the analyst and broker recommendations for Bioventus?
The overall consensus recommendation for Bioventus is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Bioventus dividend yield?
Bioventus does not currently pay a dividend.
Does Bioventus pay a dividend?
Bioventus does not currently pay a dividend.
When does Bioventus next pay dividends?
Bioventus does not currently pay a dividend.
How do I buy Bioventus shares?
To buy shares in Bioventus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bioventus?
As of the previous close price of $4.48, shares in Bioventus had a market capitalisation of $354.66m.
Where are Bioventus shares listed?
Here are the trading details for Bioventus:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BVS
What kind of share is Bioventus?
Based on an overall assessment of its quality, value and momentum Bioventus is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bioventus share price forecast for 2024?
The analyst consensus target price for shares in Bioventus is $8.00. That is 78.57% above the last closing price of $4.48.
Analysts covering Bioventus currently have a consensus Earnings Per Share (EPS) forecast of -$0.06 for the next financial year.
What is the trend in the Bioventus share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioventus. Over the past six months, its share price has outperformed the S&P500 Index by +25.52%.
As of the last closing price of $4.48, shares in Bioventus were trading +7.23% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bioventus PE Ratio?
The Bioventus PE ratio based on its reported earnings over the past 12 months is 28.54. The shares last closed at $4.48.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bioventus?
Bioventus' management team is headed by:
- William Hawkins - NEC
- Kenneth Reali - CEO
- Gregory Anglum - CFO
- Alessandra Pavesio - SVP
- Katrina Church - SVP
- Anthony D'adamio - SVP
- Sharon Klugewicz - SVP
- John Nosenzo - OTH
- Mary Ladone - DRC
- Patrick Beyer - IND
- Philip Cowdy - IND
- Michelle Mcmurry - Heath - IND
- Guido Neels - IND
- Guy Nohra - IND
- Susan Stalnecker - IND
- Martin Sutter - IND
- Stavros Vizirgiankis - IND